Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer's 4Q Revenues up 12% | Contract Pharma

What are you searching for?

Sign in
Financial News

Pfizer’s 4Q Revenues up 12%

COVID-19 vaccine BNT162b2, which was granted an EUA in the U.S. in December 2020, contributed $154 million in sales in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer
4Q Revenues: $11.7 billion (+12%)
4Q Earnings: $594 million (loss of $337 million 4Q20)
FY Revenues: $41.9 billion (+2%)
FY Earnings: $9.6 billion (-41%)
Comments: Growth primarily driven by strong performances from Vyndaqel/Vyndamax, Eliquis, Oncology Biosimilars, Ibrance, Prevenar 13 Outside of the U.S., Inlyta, Xeljanz and Xtandi.
Vyndaqel/Vyndamax sales were $429 million in the quarter, up 96%. Eliquis alliance revenues and direct sales were $1.3 billion, up 15%. Ibrance sales were $1.4 billion, up 12%. Prevenar 13 sales were $1.8 billion, up 11%. Inlyta sales were up 42% to $228 million. Xeljanz sales were up 15% to $696 million. Xtandi alliance revenues were $283 million, up 16%. BNT162b2, which was granted an emergency use authorization (EUA) in the U.S. in December 2020, contributed $154 million in sales in the quarter. Biosimilar sales were up 88% to $525 million, primarily driven by recent oncology biosimilar launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab). R&D expenses were up 21% to $3.4 billion in the quarter. The Upjohn Business is now accounted for as a discontinued operation.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters